-
ARWR Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Arrowhead Pharmaceuticals (ARWR)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 24 | Sep 23 | Sep 22 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 53.89 mm | 53.89 mm | 53.89 mm | 53.89 mm | 53.89 mm | 53.89 mm |
Cash burn (monthly) | 16.27 mm | 360.50 k | 58.37 mm | 54.25 mm | 48.76 mm | 40.94 mm |
Cash used (since last report) | 33.84 mm | 750.01 k | 121.44 mm | 112.87 mm | 101.44 mm | 85.18 mm |
Cash remaining | 20.05 mm | 53.14 mm | -67.55 mm | -58.99 mm | -47.55 mm | -31.29 mm |
Runway (months of cash) | 1.2 | 147.4 | -1.2 | -1.1 | -1.0 | -0.8 |
13F holders | Current |
---|---|
Total holders | 272 |
Opened positions | 45 |
Closed positions | 44 |
Increased positions | 89 |
Reduced positions | 87 |
13F shares | Current |
---|---|
Total value | 1.81 tn |
Total shares | 99.79 mm |
Total puts | 490.10 k |
Total calls | 520.70 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 16.18 mm | $304.15 bn |
Vanguard | 12.18 mm | $229.06 bn |
Avoro Capital Advisors | 11.11 mm | $208.89 bn |
STT State Street | 6.02 mm | $113.11 bn |
Slate Path Capital | 5.23 mm | $98.36 bn |
FMR | 5.10 mm | $95.90 bn |
Geode Capital Management | 2.95 mm | $55.57 bn |
Siren, L.L.C. | 2.90 mm | $54.55 bn |
T. Rowe Price Investment Management | 2.51 mm | $47.14 mm |
Norges Bank | 2.05 mm | $38.62 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Feb 25 | Anzalone Christopher Richard | Common Stock | Grant | Acquire A | No | No | 20.1 | 9,550 | 191.96 k | 3,773,802 |
6 Feb 25 | Ingram Douglas S | Common Stock | Grant | Acquire A | No | No | 20.09 | 38,396 | 771.38 k | 38,396 |
23 Jan 25 | Olukotun Adeoye Y | Common Stock | Sell | Dispose S | No | Yes | 21 | 959 | 20.14 k | 35,781 |
7 Jan 25 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | Yes | 19.69 | 8,000 | 157.52 k | 527,201 |
6 Jan 25 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | Yes | 20.1 | 9,526 | 191.47 k | 535,201 |
6 Jan 25 | Patrick O'Brien | Common Stock | Sell | Dispose S | No | Yes | 19.69 | 19,658 | 387.07 k | 544,727 |
4 Jan 25 | Patrick O'Brien | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 564,385 |